Table 1 Group demographics and clinical scores of the final sample.

From: A multicentre study on grey matter morphometric biomarkers for classifying early schizophrenia and parkinson’s disease psychosis

Psychosis

 

Con-Psy

ARMS

FEP

comp.

 

Cambridge

HCP

Singapore

Total

Cambridge

Singapore

Total

Cambridge

HCP

Total

KW-X2/P-X2, X2(df), p-value

n

49

57 (2x*)

39 (****)

145

32

74 (****)

106

23

123

146

n/a

Age, mean/SD (range)

23.18/3.37 (18–33)

24.88-4.08 (17–36)

22.51-3.96 (14–29)

23.67/3.93 (14–36)

21.44/3.29 (18–29)

21.46/3.43 (14–29)

21.45/3.38 (14–29)

22.78/5.18 (17–32)

22.84/3.86 (17–35)

22.83-4.07 (17–35)

22.15(2), <0.001

Sex, female

23

20

16

59

13

22

35

10

48

58

1.72(2), 0.4

CAARMS

n/a

16.56/7.57 (4–29)

16.05/7.47 (3–38)

16.21/7.47 (3–38)

-

-

-

n/a

PANSS

n/a

20.13/5.46 (14–38)

-

20.13/5.46 (14–38)

25.62/7.67 (16–51)

49.91/11.04 (30–78)

46.10/13.78 (16–78)

n/a

Medicated *****

 

0 (1 missing)

2

2

1 (1 missing)

90 (2 missing)

91

n/a

Parkinson’s Disease

 

Con-PD

PDP

PDN

 
 

Cambridge

Bangalore

Sydney

Total

Cambridge

Bangalore

Sydney

Total

Cambridge

Bangalore

Sydney

Total

 

n

25 (***)

41

22

88

15

42

35 (**,***)

92

28

49 (*)

68 (2x*,****)

145

n/a

Age

62.2/5.92 (46-72)

55.42/5.23 (44-66)

67.73/8.17 (52-87)

60.42/8.03 (44-87)

61.93/7.47 (44-73)

58.43/8.54 (38-69)

65.83/7.02 (52-82)

61.82/8.45 (38-82)

63.07/9.58 (43-74)

57.87/6.84 (42-70)

66.84/8.66 (45-87)

63.08/9.14 (42-87)

7.27(2), 0.03

Sex, female

13

10

12

35

7

8

12

27

10

3

16

29

10.74 (2), 0.005

Hoehn&Yahr ******

n/a

1.71/0.91(1–3)

2.35/0.25(2–3)

2.09/0.46 (1–3)

2.16/0.53 (1–3)

1.48/0.90(1–5)

2.32/0.30(1.5–3)

2.11/0.76(1–5)

2.08/0.72(1–5)

n/a

UPDRS, Psychosis Scale

n/a

1.53/0.78 (1–3)

2.21/1.22 (1–4)

1.37/0.65 (1–3)

1.78/1.04 (1–4)

n/a

n/a

MMSE ******

29.5/079 (27–30)

29.15/0.91 (27–30)

29.74/0.56 (28–30)

29.37/0.84 (27–30

28.00/1.75 (24–30)

28.32/1.47 (26–30)

28.74/1.28 (7–30)

28.37/1.49 (24–30)

28.74/1.66 (25–30)

28.06/1.30 (25–30)

29.40/1.05 (27–30)

28.70/1.42 (25–30)

19.38 (2), <0.001

Medicated*******

n/a

15/0

42/0

34/0

91/0

28

49

63

140

n/a

  1. Exclusion criteria from original data: * Missing files; ** faulty scan; *** listed multiple times; **** excluded during segmentation.
  2. ***** any current antipsychotic treatment, yes (N).
  3. ****** mean/SD (range).
  4. ******* Levodopa / antipsychotic, yes (N).
  5. KW-X2 Kruskal–Wallis rank-sum test, P-X2 Pearson’s Chi-squared test.
Back to article page